Age: 27
Free Agency: 2022 (UFA)
Accrued Seasons: 5
- Height: 6'4"
- Weight: 332
- College: Texas A&M
- Entry: 2017 Draft, Round 5, #159 overall (Ravens)
- 2021 Salary Cap Charge: $850,000 (0.45% of cap)
- 2021 Cash Payout: $990,000 (0.54% of spending)
- 2021 Cash to Cap Ratio: 1.16
- Contract Value: $990,000 ($990,000 APY)
- Fully Guaranteed Money: $0
- Contract Ranking: 39/109 at RG
Current Contract
(SFA, signed 2021)
(📝: indicates contract trigger occuring during that year)| Year | Age | Base Salary | Cap Number | Cap % | Dead Money & Cap Savings | |||
|---|---|---|---|---|---|---|---|---|
| 2021 | 27 | $990,000 | $850,000 | 0.4% | ||||
| Total | $990,000 | $850,000 | ||||||
Contract Notes
Jermaine Eluemunor was tendered at the lowest RFA level by the Patriots. Eluemunor signed the one year contract offer on April 16, 2020. The contract is worth $2.133 million.
Cash Flows
| 2021 | |
|---|---|
| Cash Due | $990,000 |
| Running Cash | $990,000 |
Career Earnings: $5,104,576
Career APY: $1,020,915
Contract History
| Team | Contract Type | Status | Year Signed | Yrs | Total | APY | Guarantees | Amount Earned | % Earned | Effective APY |
|---|---|---|---|---|---|---|---|---|---|---|
| Ravens | Drafted | Terminated | 2017 | 4 | $2,667,164 | $666,791 | $267,164 | $732,164 | 27.5% | $732,164 |
| Ravens | Practice | Terminated | 2018 | 1 | $340,000 | $340,000 | $0 | $0 | 0.0% | $0 |
| Ravens | SFA | Expired | 2018 | 1 | $555,000 | $555,000 | $0 | $326,471 | 58.8% | $326,471 |
| Ravens | ERFA | Traded | 2019 | 1 | $645,000 | $645,000 | $0 | $0 | 0.0% | $0 |
| Patriots | ERFA | Expired | 2019 | 1 | $645,000 | $645,000 | $0 | $645,000 | 100.0% | $645,000 |
| Patriots | RFA | Expired | 2020 | 1 | $2,133,000 | $2,133,000 | $0 | $2,133,000 | 100.0% | $2,133,000 |
| Dolphins | SFA | Terminated | 2021 | 1 | $1,127,500 | $1,127,500 | $100,000 | $0 | 0.0% | $0 |
| Jaguars | SFA | Terminated | 2021 | 1 | $990,000 | $990,000 | $0 | $0 | 0.0% | $0 |
| Raiders | SFA | Active | 2021 | 1 | $990,000 | $990,000 | $0 | $990,000 | 100.0% | $990,000 |
Earnings By Team
| Team | Yrs | Salary | APY | Paid on Cap | % Paid on Cap | Paid as Dead Money | % Paid as Dead Money |
|---|---|---|---|---|---|---|---|
| Ravens | 2 | $1,236,576 | $618,288 | $858,262 | 0.0% | $378,314 | 0.0% |
| Patriots | 2 | $2,778,000 | $1,389,000 | $2,778,000 | 0.0% | $0 | 0.0% |
| Dolphins | 0 | $100,000 | $0 | $0 | 0.0% | $100,000 | 0.0% |
| Jaguars | 0 | $0 | $0 | $0 | 0.0% | $0 | 0.0% |
| Raiders | 1 | $990,000 | $990,000 | $850,000 | 0.0% | $0 | 0.0% |
Season History
| Year | Team | Base Salary | Prorated Bonus | Cap Number | Cap % | Cash Paid | |
|---|---|---|---|---|---|---|---|
| 2017 | Ravens | $465,000 | $66,791 | $531,791 | 0.3% | $732,164 | |
| 2018 | Ravens | $555,000 | $0 | $326,471 | 0.2% | $326,471 | |
| 2019 | Patriots | $645,000 | $0 | $645,000 | 0.3% | $645,000 | |
| 2020 | Patriots | $2,133,000 | $0 | $2,133,000 | 1.0% | $2,133,000 | |
| 2021 | Raiders | $990,000 | $0 | $850,000 | 0.4% | $990,000 | |
| Total | $4,788,000 | $66,791 | $4,486,262 | $4,826,635 | |||
Statistics
| Year | Games Played | Games Inactive | Snaps | ||
|---|---|---|---|---|---|
| Injured | Healthy | Offense | Special | ||
| 2017 | 8 | 5 | 3 | 18.2% | 6.8% |
| 2018 | 9 | 0 | 2 | 7.9% | 9.4% |
| 2019 | 10 | 1 | 4 | 2.5% | 8.3% |
| 2020 | 12 | 0 | 0 | 41.4% | 11.7% |
| 2021 | 14 | 0 | 2 | 23.3% | 14.0% |
Valuation Diamond
The diamond is a scatterplot graph that visualizes the relation of the player's APY (in green) and performance (in blue, as measured by OTC's Valuations) to the rest of the league at his position. To understand how to read the diamond, read this explainer.
| OTC Valuation | APY | |
|---|---|---|
| Regular | $2,867,000 | $990,000 |
| Injury Adjusted | $2,867,000 | $990,000 |
Weekly Valuation Trends
The chart below illustrates the trend of the player's weekly OTC Valuations (in blue) from the most recent season, using APY (in green) and, if applicable, cash that is due to the player in the next season (in red) as benchmarks. Weeks not plotted indicate that the player was inactive or on a bye.
To see interactive and more in-depth use of OTC Valuation data, subscribe to OTC Premium.